is a glp-1 insulin Schematic of action of on secretion Frontiers | GLP-1R in diabetes

These challenges are directly informing the development of next-generation oral formulations, including alternative absorption technologies and molecular modifications aimed at improving stability and enabling more flexible dosing

The primary mechanisms of action include: Enhanced insulin secretion : GLP-1 receptor agonists stimulate glucose-dependent insulin release from pancreatic beta cells, meaning insulin is released only when blood glucose levels are elevated, reducing hypoglycemia risk when used as monotherapy (though risk increases when combined with insulin or sulfonylureas)

doi: 10.1016/S0140-6736(18)31773-2

To understand what that means for safety, see the treatment options section